Peter A. Ljubenkov, MD, is a behavioral neurologist at the UCSF Edward and Pearl Fein Memory and Aging Center, where he specializes in caring for patients experiencing cognitive, language, and behavioral changes due to neurological conditions such as Alzheimer’s disease, Lewy body dementia, and other forms of dementia. He has particular expertise in diagnosing and treating frontotemporal dementia and related conditions, including progressive supranuclear palsy and corticobasal degeneration.
Dr. Ljubenkov serves as the director of the UCSF Alzheimer’s Infusion Core and the associate director of the Alzheimer’s Disease and Frontotemporal Degeneration Clinical Trials Program at Fein Memory and Aging Center. He is deeply involved in clinical trials investigating potential therapies for neurodegenerative diseases. His research focuses on identifying biomarkers for frontotemporal dementia, with an emphasis on understanding the role of immune system dysregulation in disease progression.
Dr. Ljubenkov earned his medical degree from the Lewis Katz School of Medicine at Temple University. He completed an internal medicine internship at the University of California, Irvine, followed by a neurology residency at the University of California, San Diego. He then completed a fellowship in behavioral neurology at UCSF and joined the faculty. Since joining UCSF, Dr. Ljubenkov has been actively engaged in research through the Boxer Lab, which is dedicated to advancing treatments and understanding of frontotemporal lobar degeneration. He also served as the 2017–2018 Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) research fellow.